This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6qsx
From Proteopedia
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Complement factor B protease domain in complex with the reversible inhibitor ((2S,4S)-1-((5,7-dimethyl-1H-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)methanol.== | |
| - | + | <StructureSection load='6qsx' size='340' side='right'caption='[[6qsx]], [[Resolution|resolution]] 1.77Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[6qsx]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6QSX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6QSX FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=JGN:[(2~{S},4~{S})-1-[(5,7-dimethyl-1~{H}-indol-4-yl)methyl]-4-methoxy-piperidin-2-yl]methanol'>JGN</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | |
| - | [[Category: | + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Alternative-complement-pathway_C3/C5_convertase Alternative-complement-pathway C3/C5 convertase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.47 3.4.21.47] </span></td></tr> |
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6qsx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6qsx OCA], [http://pdbe.org/6qsx PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6qsx RCSB], [http://www.ebi.ac.uk/pdbsum/6qsx PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6qsx ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Disease == | ||
| + | [[http://www.uniprot.org/uniprot/CFAB_HUMAN CFAB_HUMAN]] Defects in CFB are a cause of susceptibility to hemolytic uremic syndrome atypical type 4 (AHUS4) [MIM:[http://omim.org/entry/612924 612924]]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.<ref>PMID:17182750</ref> <ref>PMID:20513133</ref> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/CFAB_HUMAN CFAB_HUMAN]] Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes. | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Alternative-complement-pathway C3/C5 convertase]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Adams, C M]] | ||
| + | [[Category: Anderson, K]] | ||
| + | [[Category: Argikar, U]] | ||
| + | [[Category: Crowley, M]] | ||
[[Category: Cumin, F]] | [[Category: Cumin, F]] | ||
| - | [[Category: Crowley, M]] | ||
[[Category: Eder, J]] | [[Category: Eder, J]] | ||
| - | [[Category: | + | [[Category: Ehara, T]] |
| + | [[Category: Erbel, P]] | ||
| + | [[Category: Flohr, S]] | ||
| + | [[Category: Gerhartz, B]] | ||
| + | [[Category: Harrison, R]] | ||
| + | [[Category: Hughes, N]] | ||
| + | [[Category: Jaffee, B]] | ||
| + | [[Category: Karki, R]] | ||
| + | [[Category: Maibaum, J]] | ||
[[Category: Mainolfi, N]] | [[Category: Mainolfi, N]] | ||
| - | [[Category: | + | [[Category: Mogi, M]] |
| - | + | ||
| - | + | ||
[[Category: Sedrani, R]] | [[Category: Sedrani, R]] | ||
| - | [[Category: | + | [[Category: Sellner, H]] |
[[Category: Sirockin, F]] | [[Category: Sirockin, F]] | ||
| - | [[Category: | + | [[Category: Smith, T M]] |
| - | [[Category: | + | [[Category: Sweeney, A Mac]] |
| - | [[Category: | + | [[Category: Valeur, E]] |
[[Category: Wiesmann, C]] | [[Category: Wiesmann, C]] | ||
| - | [[Category: | + | [[Category: C3 convertase]] |
| - | [[Category: | + | [[Category: Complement]] |
| - | [[Category: | + | [[Category: Hydrolase]] |
| - | [[Category: | + | [[Category: Immune]] |
| - | [[Category: | + | [[Category: Inhibitor]] |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
Revision as of 06:49, 27 March 2019
Complement factor B protease domain in complex with the reversible inhibitor ((2S,4S)-1-((5,7-dimethyl-1H-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)methanol.
| |||||||||||
Categories: Alternative-complement-pathway C3/C5 convertase | Large Structures | Adams, C M | Anderson, K | Argikar, U | Crowley, M | Cumin, F | Eder, J | Ehara, T | Erbel, P | Flohr, S | Gerhartz, B | Harrison, R | Hughes, N | Jaffee, B | Karki, R | Maibaum, J | Mainolfi, N | Mogi, M | Sedrani, R | Sellner, H | Sirockin, F | Smith, T M | Sweeney, A Mac | Valeur, E | Wiesmann, C | C3 convertase | Complement | Hydrolase | Immune | Inhibitor
